Cryopreservation in cell therapy and gene therapy manufacturing is critical to maintaining product integrity. The components used in the production of cell and gene therapies must be able to withstand temperatures of -130°C and lower – as well as the freeze-thaw cycles associated with processing, transportation, and administration to patients.

The CGT industry is moving toward applying biopharmaceutical best practices in a way that meets CGT requirements. This white paper covers key issues in CGT processing including:

READ WHITE PAPER

CPC set the industry standard for sterile connection technologies with its AseptiQuik® G Series. It now offers the first aseptic connector solutions designed specifically for cryopreservation in CGT applications, featuring the MicroCNX® ULT Series.

CPC is the industry leader in aseptic sterile connection technology